研究单位:[1]Peking University People's Hospital[2]Beijing Hospital[3]Navy General Hospital,Beijing[4]Beijing Aerospace General Hospital[5]Qilu Hospital of Shandong University[6]Beijing Tongren Hospital
Randomized, open-label, multicenter study to compare the efficacy and safety of zanubrutinib plus high-dose dexamethasone compared to high-dose dexamethasone monotherapy for the first-line treatment of adults with primary immune thrombocytopenia (ITP).